L'Hopital Prive Du Confluent — Clinical Trial Site

105 Registered trials

49 Currently recruiting

Organisation

L'Hopital Prive Du Confluent

Location

Nantes Cedex 2, France

Identifier

ORG-100041120

Address

4 Rue Eric Tabarly, 44277, France

Departments

#5024: Hématologie
Algology
Clinical Oncology
Consultations d'Hématologie
Département d’Hématologie
Département de Cardiologie
Department of Medical Oncology
Hématologie
Hématologie Oncologie
Hematology
Interventional Cardiology and Care Unit
Medical oncology
Medical Oncology Department
N/A
oncolgy
Oncological Department
oncologie
Oncologie Médicale
Oncology
Radiothérapie
Radiotherapy
Service d'hématologie
Service d'oncologie médicale
Service d’hématologie
Service d’Oncologie Médicale
SERVICE DE CARDIOLOGIE
Service Oncologie Médicale
Services d’oncologie
Services d’oncologie medicale
Spécialité Oncologie médicale, Hématologie, Chimiothérapie

Clinical trials at this site (105)

Search interface

Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5
A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed mult… Pending

2025-520976-25-00 Relapsed/refractory multiple myeloma 4
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac… Pending

2025-521090-14-00 Patients with relapsed/refractory symptomatic multiple 4
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending

2025-521199-80-00 Patients with previously untreated symptomatic chronic 4
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Treatment-naїve mantle cell lymphoma (MCL) 5
A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting

2025-523742-27-00 Advanced solid tumors 9 2026-04-28
Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting

2024-519444-33-00 HER2-expressing endometrial cancer (IHC 3+/2+) 5 2026-03-12
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting

2022-500461-28-06 High-Risk Metastatic Hormone-Sensitive Prostate Cancer 5 2022-09-15
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev… Recruiting

2023-505781-28-00 Patients with Waldenstrom macroglobulinemia and have re 4 2026-01-20
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07